ALBERTA PRECISION LABORATORIES Leaders in Laboratory Medicine		Molecular Genetics Laboratory Cancer and Endocrine NGS Requisition For detailed testing information, refer to APL Genetics & Genomics Webpage http://ahsweb.ca/lab/if-lab-genetics-and-genomics and APL Test Directory http://ahsweb.ca/lab/apl-td-lab-test-directory						Scanning Label or Accession # (lab only)			
	PHN	Expiry:			Date of Birth (dd-Mon-yyyy)						
<b>int</b>	Legal Last Name			Legal First Name			Middle Name				
Patient	Alternate Identifier		Preferred I	Name	□ Male □ Non-binary	□ Ferr □ Pref	ale er not to d	isclose	Phone		
	Address		1	City/Town	1		Prov			Postal Code	
	Authorizing Provider Name (last, first, mide				<i>lle)</i> Copy to Name		ne (last, fi	irst, middle) Copy to Name (last, first, midd		e (last, first, middle)	
er(s	Address	Address			Phone Address				Address		
Provider(s)	CC Provider	er ID CC Su		bmitter ID	Legacy ID	Phone	Phone		Phone		
Pr	Clinic Name	Clinic Name				Clinic Name	Clinic Name		Clinic Name		
Collection		Date (dd-Mon-y		ууу)	Time (24 hr)	Location	Location		Collector ID		
Genetic Couns		ellor/Clinic Contact Nam			e (last, first)				Phone		
Specimen         Whole Blood in EDTA tube       Extracted DNA       Fluid, amniotic*         Tissue, chorionic villi*       Cord blood*       Other (specify)         *If specimen type is prenatal or cord blood, maternal specimen must be collected for maternal cell contamination studies         Health Care Provider Important Information         1. All sections of the requisition must be completed.         2. By providing this requisition to the patient/family, the health care provider confirms that they have reviewed the pre-test counselling information (available on the Genetics & Genomics website) with the patient/family, and the patient/family consents to testing.         3. Direct patient to take requisition to a local blood collection location to have blood specimen drawn.											
Billing Information: Must be completed if the patient does not have a valid Alberta Personal Heath Number         Genetic testing is not covered by inter-provincial billing agreements. Alberta Precision Laboratories (APL) will bill a         provincial medical services plan provided there is a letter of pre-approval received with the requisition or Institutional         Billing information provided below. By completing the Institutional Billing section, the health care provider confirms         they have obtained any necessary pre-approval. For patient pay, contact the testing laboratory.         Institutional Billing Information ( <i>if pre-approval letter not attached</i> )         Address         Contact Name ( <i>last, first</i> )         Phone       Fax											
MGL Use Only											
Patient Number Family Nu			mber	Received			Quanti	ity			

Last Name (Legal)

000			
ALBERTA Precision Laboratories			
Leaders in Laboratory Medicine			

## Molecular Genetics Laboratory Cancer and Endocrine NGS Requisition

PHN

Section I - Reason for Testing (Select one only)	Section II - Family History of Indicated Disease				
Confirmation of Diagnosis Patient has signs or symptoms of the disease / disorder.	□ Unknown family history				
□ Presymptomatic or Predictive Testing	□ No known family history				
Patient does not presently have symptoms; positive family history	□ Possible family history				
□ Carrier Testing.	Documented family history				
No symptoms; at risk of being a carrier of a recessive disorder	Clinical Diagnosis ONLY				
Required for Family Study	Molecular Diagnosis (provide a copy of the familial variant report and complete information in Section V)				
Prenatal Testing					
□ Other					
Is RUSH testing needed?  Yes (provide details below)	1				
□ Results will alter the <b>immediate</b> management and/or treatment of this patient (specify)					
Results will impact an ongoing pregnancy (provide EDD, and procedure date if applicable)					
If RUSH testing is required, please provide a target date (c Note: TAT is a minimum of 4 weeks.	dd-Mon-yyyy) (required)				
Section III - Patient Clinical Information					
Sex at birth	□ Male □ Unknown				
Date of last chemotherapy (if applicable) $\rightarrow$ Date (dd-Mon-yy	/yy)				
Has this patient received a blood product in the preceding three months?					
	te blood product				
Has the patient had a bone marrow transplant?					
Please provide any relevant information regarding your patient's primary tumour, pathology, hormone receptors)	clinical presentation (ex. tumour site, age at diagnosis, multiple				
If applicable, IHC result (required for Lynch testing)					
Has the patient had BRCA 1/2 testing of tumour tissue?					
Section IV - Pedigree (Provide any relevant family history details, with fa	amily member names, ages, and diagnoses included as applicable. If more space				
<i>is required, attach a separate sheet.)</i> Patient Ethnicity/Ancestry					



PHN

Section V - Specific Variant Testing							
Complete this section only if you are requesting testing for a variant previously identified in the family. Specific variant testing is available for all genes available on the panels listed below.							
Inherited Cancer and Endocrine Gene Panels, Specific Variant							
Gene Mutation/Variant							
Relationship to index patient							
What is the phenotype/presentation in the index patient?							
Other family members previously tested in MGL □ No □ Yes ▼							
INDEX patient name MGL Reference Number							
Which laboratory performed the proband testing?   Calgary   Edmonton   Other (specify)							
Testing a positive control is recommended if the proband testing was performed at another lab.							
A clear copy of the test report on a family member is required if the testing was performed at another laboratory							
Section VI - Cancer and Endocrine NGS Panel Requests							
Breast, Ovarian and Prostate Cancers							
Breast, Ovarian and Prostate Cancers							
Endocrine Disorders							
Endocrine Neoplasia Panel							
□ Paraganglioma/Pheochromocytoma Predisposition Panel							
Renal Cancer Panel							
Gastrointestinal Cancers							
□ Gastrointestinal/Polyposis Panel							
Gastrointestinal Stromal Tumor Panel							
Lynch Syndrome Panel							
Pancreatic Cancer Panel							
Hematological Cancers							
<ul> <li>Familial Acute Myeloid Leukemia Panel</li> <li>Fanconi Anemia and DNA Repair Disorders Panel</li> </ul>							
Overgrowth Disorders							
Hereditary Multiple Osteochondromatosis Panel							
Overgrowth Panel							
Pediatric Cancers							
Pediatric Cancers     Pediatric Cancer Panel							
□ Schwannomatosis Panel							
Tuberous Sclerosis							
Skin Cancers							
□ Skin Cancer Panel							
□ Xeroderma Pigmentosum Panel							



PHN

Section VII - Single Gene Test Request						
CASR-Related Disorder						
□ Inherited Cancer and Endocrine Single Gene (complete only if panel is not appropriate for patient)						
Requesting test for	(indicate the gene) <b>and</b> the presenting phenotype					
Requesting test for	(indicate the gene) and the presenting phenotype					
□ Neurofibromaosis Type 1 <i>Please indicate if your patient has the following</i>						
□ Greater than 6 café-au-lait macules greater than 5 mm, postpubertal greater than 15 mm						
□ Greater than 2 neurofibromas or 1	plexiform neurofibroma					
Axillary or inguinal freckling	□ Axillary or inguinal freckling					
□ Optic glioma	□ Optic glioma					
□ Greater than 2 Lisch nodules						
□ A distinctive osseous lesion						
□ A first degree relative with NF1 per the above critera						
If the patient does not fulfill NIH diagnostic criteria for NF1, please provide reason for testing as a comment						
Section VIII - Variant Reinterpretation						

Complete this section only if you are requesting reinterpretation of a variant previously identified in the family

Gene	Mutation/Variant
What is the clinical phenotype/presentation in the family?	

## A clear copy of the test report is required if the testing was preformed at another laboratory

## Section IX - Additional Comments